Dr Max Mirza

Max is a highly-experienced neuroscientist whose career spans over 25 years in biotech as well as big- and mid-size pharma. He has run and overseen multiple drug discovery projects from medicinal chemistry through to Phase 2a, working with internal teams, CROs, academics and investors to progress projects taking a stage-gated, decision-guided approach. At the biotech NeuroSearch Max was involved in several multi-year collaborations with major pharma companies focused on CNS and pain projects from research to early clinical development. He was Co-founder and CSO of the CNS-focused biotech Saniona, listed on the Stockholm Nasdaq. At Pfizer, he was part of the external R&D team focused on bolstering the internal pain and neuroscience pipeline and capabilities, working closely with commercial and BD teams, with an emphasis on novel therapeutic modalities. Prior to joining Sygnature Discovery, Max was at Mundipharma where he was responsible for innovating in pain, neuroscience, metabolic disorders, and infectious disease also working closely with commercial and reimbursement teams. Max continues to consult on neuroscience for various venture capital firms and investment teams.